Disitamab vedotin plus radiation for high-risk bladder cancer in kidney tube
Treatments studied
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had surgery to remove a kidney and ureter for cancer in the upper urinary tract
- Your cancer stage after surgery is pT3-pT4N0M0 or had spread to lymph nodes (pTxN+)
- Your cancer cells tested as 1+, 2+, or 3+ for a protein called HER2
- You cannot take cisplatin chemo because of poor kidney function, hearing loss, nerve damage, heart failure, or being frail (ECOG 2)
- You have not had other cancer treatments before this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (disitamab vedotin and tislelizumab) designed to treat a type of cancer in the upper urinary tract (kidney and ureter) while preserving kidney function. It's for patients with HER2-positive tumors who want to avoid or cannot have kidney removal surgery.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial studies a combination of two drugs for bladder cancer that has not spread beyond the bladder. It aims to help patients who want to avoid bladder removal surgery, potentially preserving their bladder.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
This Phase 2 trial studies a targeted drug (disitamab vedotin) given with radiation to help people keep their bladder after muscle-invasive bladder cancer. You may be eligible if your tumor is in the bladder, has a certain lab marker on biopsy, and imaging shows it fits a specific stage.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.